drugset
drugset / Trial / NCT03510598

Submental Study (Sequential Treatment Approach)

NCT03510598 ↗

Phase 4 Completed 16 enrolled Zeltiq Aesthetics
NaSequentialOpen-labelTreatment

Summary

Evaluate the safety and efficacy of subcutaneous fat layer reduction in the submental area using multiple therapeutic tools.

Timeline

Start
2018-03-27
Primary completion
2018-12-08
Completion
2018-12-08

Drugs

EvaluationDrugModalityDoseRoute
Subject ATX-101 Peptide 20 mg —

Indications

obesity disorder